Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Epidermal growth factor receptor (EGFR) is crucial for solid tumor growth and invasion.
• Monoclonal antibodies (mAbs) are effective cancer therapies, but their efficacy relies on specificity and potency.

Purpose of the Study:

• To generate and characterize novel anti-EGFR monoclonal antibodies for potential cancer diagnostics and treatment.
• To evaluate the specificity and efficacy of a newly developed mAb against EGFR-expressing cancer cells.

Main Methods:

• Hybridoma technology was employed to produce monoclonal antibodies against human EGFR.
• Immunization of Balb/c mice with EGFR-positive A431 cancer cells.
• Characterization of antibody specificity using ELISA, flow cytometry, and immunofluorescence staining.
• Assessment of anti-cancer activity via MTT assay to determine growth inhibition and apoptosis induction.

Main Results:

• A specific IgG1 monoclonal antibody, designated mAb BF4, was successfully generated.
• mAb BF4 demonstrated specific binding to EGFR-expressing A431 cells.
• Treatment with mAb BF4 significantly inhibited A431 cell growth, primarily by inducing apoptosis.

Conclusions:

• The novel anti-EGFR mAb BF4 exhibits specific reactivity and potent anti-proliferative effects on EGFR-overexpressing cancer cells.
• mAb BF4 holds potential for development as a diagnostic tool and therapeutic agent for various malignancies.
• Further investigation into the therapeutic applications of mAb BF4 in EGFR-driven cancers is warranted.